Bios Fund Ii Nt, Lp - Net Worth and Insider Trading

Bios Fund Ii Nt, Lp Net Worth

The estimated net worth of Bios Fund Ii Nt, Lp is at least $348,902 dollars as of 2024-11-13. Bios Fund Ii Nt, Lp is the Director, 10% Owner of IN8bio Inc and owns about 997,433 shares of IN8bio Inc (INAB) stock worth over $348,902. Details can be seen in Bios Fund Ii Nt, Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bios Fund Ii Nt, Lp has not made any transactions after 2022-08-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Bios Fund Ii Nt, Lp

Bios Fund Ii Nt, Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bios Fund Ii Nt, Lp owns 4 companies in total, including Lantern Pharma Inc (LTRN) , Cognition Therapeutics Inc (CGTX) , and IN8bio Inc (INAB) among others .

Click here to see the complete history of Bios Fund Ii Nt, Lp’s form 4 insider trades.

Insider Ownership Summary of Bios Fund Ii Nt, Lp

Ticker	Comapny	Transaction Date	Type of Owner
LTRN	Lantern Pharma Inc	2022-09-02	10 percent owner
CGTX	Cognition Therapeutics Inc	2022-11-15	10 percent owner
INAB	IN8bio Inc	2022-08-29	director & 10 percent owner
		2023-06-15	10 percent owner

Bios Fund Ii Nt, Lp Latest Holdings Summary

Bios Fund Ii Nt, Lp currently owns a total of 1 stock. Bios Fund Ii Nt, Lp owns 997,433 shares of IN8bio Inc (INAB) as of August 29, 2022, with a value of $348,902.

Latest Holdings of Bios Fund Ii Nt, Lp

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
INAB	IN8bio Inc	2022-08-29	997,433	0.35	348,902

Holding Weightings of Bios Fund Ii Nt, Lp

Bios Fund Ii Nt, Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Bios Fund Ii Nt, Lp has made a total of 3 transactions in IN8bio Inc (INAB) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in IN8bio Inc is the acquisition of 51,214 shares on August 29, 2022, which cost Bios Fund Ii Nt, Lp around $103,452.

Insider Trading History of Bios Fund Ii Nt, Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bios Fund Ii Nt, Lp Trading Performance

GuruFocus tracks the stock performance after each of Bios Fund Ii Nt, Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bios Fund Ii Nt, Lp is -24.58%. GuruFocus also compares Bios Fund Ii Nt, Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bios Fund Ii Nt, Lp within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bios Fund Ii Nt, Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bios Fund Ii Nt, Lp

Average Return

Average return per transaction

Outperforming Transactions

0 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	8.58
Relative Return to S&P 500(%)	18.16

Bios Fund Ii Nt, Lp Ownership Network

Ownership Network List of Bios Fund Ii Nt, Lp

No Data

Ownership Network Relation of Bios Fund Ii Nt, Lp

Bios Fund Ii Nt, Lp Owned Company Details

What does Lantern Pharma Inc do?

Who are the key executives at Lantern Pharma Inc?

Bios Fund Ii Nt, Lp is the 10 percent owner of Lantern Pharma Inc. Other key executives at Lantern Pharma Inc include 10 percent owner Leslie W. Kreis , 10 percent owner Bios Fund I, Lp , and 10 percent owner Fletcher Aaron G.l. .

Lantern Pharma Inc (LTRN) Insider Trades Summary

Over the past 18 months, Bios Fund Ii Nt, Lp made no insider transaction in Lantern Pharma Inc (LTRN). Other recent insider transactions involving Lantern Pharma Inc (LTRN) include a net sale of 378,237 shares made by Leslie W. Kreis , and a net sale of 378,237 shares made by Bios Fund I, Lp .

In summary, during the past 3 months, insiders sold 0 shares of Lantern Pharma Inc (LTRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 756,474 shares of Lantern Pharma Inc (LTRN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 756,474 shares.

Lantern Pharma Inc (LTRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lantern Pharma Inc Insider Transactions

No Available Data

What does Cognition Therapeutics Inc do?

Who are the key executives at Cognition Therapeutics Inc?

Bios Fund Ii Nt, Lp is the 10 percent owner of Cognition Therapeutics Inc. Other key executives at Cognition Therapeutics Inc include director & CEO & President Lisa Ricciardi , Chief Financial Officer John Brendan Doyle , and Chief Medical Officer Anthony Caggiano .

Cognition Therapeutics Inc (CGTX) Insider Trades Summary

Over the past 18 months, Bios Fund Ii Nt, Lp made no insider transaction in Cognition Therapeutics Inc (CGTX). Other recent insider transactions involving Cognition Therapeutics Inc (CGTX) include a net purchase of 5,700 shares made by Lisa Ricciardi ,

In summary, during the past 3 months, insiders sold 0 shares of Cognition Therapeutics Inc (CGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cognition Therapeutics Inc (CGTX) were sold and 5,700 shares were bought by its insiders, resulting in a net purchase of 5,700 shares.

Cognition Therapeutics Inc (CGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cognition Therapeutics Inc Insider Transactions

No Available Data

What does IN8bio Inc do?

Who are the key executives at IN8bio Inc?

Bios Fund Ii Nt, Lp is the director & 10 percent owner of IN8bio Inc. Other key executives at IN8bio Inc include Chief Financial Officer Patrick Mccall , director & President & CEO and CFO William Tai-wei Ho , and director & 10 percent owner Bios Fund Ii, Lp .

IN8bio Inc (INAB) Insider Trades Summary

Over the past 18 months, Bios Fund Ii Nt, Lp made no insider transaction in IN8bio Inc (INAB). Other recent insider transactions involving IN8bio Inc (INAB) include a net purchase of 23,800 shares made by William Tai-wei Ho , a net purchase of 2,500 shares made by Jeremy R. Graff , and a net purchase of 1,000 shares made by Patrick Mccall .

In summary, during the past 3 months, insiders sold 0 shares of IN8bio Inc (INAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of IN8bio Inc (INAB) were sold and 27,300 shares were bought by its insiders, resulting in a net purchase of 27,300 shares.

IN8bio Inc (INAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

IN8bio Inc Insider Transactions

No Available Data

What does Azitra Inc do?

Who are the key executives at Azitra Inc?

Bios Fund Ii Nt, Lp is the 10 percent owner of Azitra Inc. Other key executives at Azitra Inc include Chief Financial Officer Norm Staskey , director & President and CEO Francisco D. Salva , and director & Chief Operating Officer Travis Whitfill .

Azitra Inc (AZTR) Insider Trades Summary

Over the past 18 months, Bios Fund Ii Nt, Lp made no insider transaction in Azitra Inc (AZTR). Other recent insider transactions involving Azitra Inc (AZTR) include a net purchase of 50,900 shares made by Norm Staskey , a net purchase of 2,297,490 shares made by Fletcher Aaron G.l. , and a net purchase of 2,297,490 shares made by Leslie W. Kreis .

In summary, during the past 3 months, insiders sold 0 shares of Azitra Inc (AZTR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Azitra Inc (AZTR) were sold and 166,473 shares were bought by its insiders, resulting in a net purchase of 166,473 shares.

Azitra Inc (AZTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Azitra Inc Insider Transactions

No Available Data

Bios Fund Ii Nt, Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Bios Fund Ii Nt, Lp. You might contact Bios Fund Ii Nt, Lp via mailing address: 1401 Foch Street, Suite 140, Fort Worth Tx 76107.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.